ArticleBMC genomics2009
The theory of discovering rare variants via DNA sequencing.
Article in BMC genomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The first five years of single-cell cancer genomics and beyond.Genome research · 2015Article
- Assessment of a targeted resequencing assay as a support tool in the diagnosis of lysosomal storage disorders.Orphanet journal of rare diseases · 2014Article
- Coverage theories for metagenomic DNA sequencing based on a generalization of Stevens' theorem.Journal of mathematical biology · 2013Article
- Sequencing studies in human genetics: design and interpretation.Nature reviews. Genetics · 2013Review
- Joint analysis of multiple metagenomic samples.PLoS computational biology · 2012Article
- Coverage tradeoffs and power estimation in the design of whole-genome sequencing experiments for detecting association.Bioinformatics (Oxford, England) · 2011Article
- Efficient study design for next generation sequencing.Genetic epidemiology · 2011Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundRare population variants are known to have important biomedical implications, but their systematic discovery has only recently been enabled by advances in DNA sequencing. The design process of a discovery project remains formidable, being limited to ad hoc mixtures of extensive computer simulation and pilot sequencing. Here, the task is examined from a general mathematical perspective.
resultsWe pose and solve the population sequencing design problem and subsequently apply standard optimization techniques that maximize the discovery probability. Emphasis is placed on cases whose discovery thresholds place them within reach of current technologies. We find that parameter values characteristic of rare-variant projects lead to a general, yet remarkably simple set of optimization rules. Specifically, optimal processing occurs at constant values of the per-sample redundancy, refuting current notions that sample size should be selected outright. Optimal project-wide redundancy and sample size are then shown to be inversely proportional to the desired variant frequency. A second family of constants governs these relationships, permitting one to immediately establish the most efficient settings for a given set of discovery conditions. Our results largely concur with the empirical design of the Thousand Genomes Project, though they furnish some additional refinement.
conclusionThe optimization principles reported here dramatically simplify the design process and should be broadly useful as rare-variant projects become both more important and routine in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.